Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2017, Vol. 44 Issue (1): 143-145    DOI: 10.12891/ceog3214.2017
Case Report Previous articles | Next articles
Low-dose gonadotropin-releasing hormone agonist therapy (draw-back therapy) for successful long-term management of adenomyosis associated with cerebral venous and sinus thrombosis from low-dose oral contraceptive use
T. Matsushima1, *(), S. Akira2, H. Asakura1, T. Takeshita2
1 Department of Obstetrics & Gynecology, Nippon Medical School, Musashikosugi Hospital, Kawasaki, Kanagawa, Japan
2 Department of Obstetrics & Gynecology, Nippon Medical School, Tokyo, Japan
Download:  PDF
Export:  BibTeX | EndNote (RIS)      
Abstract  
The authors report a case of cerebral venous and sinus thrombosis (CVST) in a patient receiving a low-dose estrogen-progestin combination (oral contraceptives, OCs) for uterine adenomyosis. She was switched to gonadotropin-releasing hormone agonist (GnRHa) draw-back therapy, which was successfully administered long-term. Case: The patient was a 38-year-old nulligravida with a history of smoking. She presented to this hospital with dysmenorrhea and postmenstrual lower abdominal pain. Adenomyosis was diagnosed using ultrasound and magnetic resonance imaging. She was instructed to stop smoking and was administered low-dose OCs. CVST occurred 18 months later. OC therapy was halted, and only antiplatelet therapy was administered. After six months, her chief complaint symptoms intensified, therefore GnRHa draw-back therapy was administered after obtaining informed consent. No uterine enlargement was observed, and the abdominal pain resolved. During 2.5 years of therapy, her bone density levels remained within normal limits. CVST did not recur and no other thromboses were observed.
Key words:  Adenomyosis      Cerebral venous and sinus thrombosis      Low-dose gonadotropin-releasing hormone agonist therapy      Low-dose oral contraceptive     
Published:  10 February 2017     
*Corresponding Author(s):  T. MATSUSHIMA     E-mail:  matsushi@nms.ac.jp

Cite this article: 

T. Matsushima, S. Akira, H. Asakura, T. Takeshita. Low-dose gonadotropin-releasing hormone agonist therapy (draw-back therapy) for successful long-term management of adenomyosis associated with cerebral venous and sinus thrombosis from low-dose oral contraceptive use. Clinical and Experimental Obstetrics & Gynecology, 2017, 44(1): 143-145.

URL: 

https://ceog.imrpress.com/EN/10.12891/ceog3214.2017     OR     https://ceog.imrpress.com/EN/Y2017/V44/I1/143

[1] Anjeza Xholli, Anna Biasioli, Giovanni Grandi, Angelo Cagnacci. Dienogest-based hormonal contraception induced changes in the ultrasound presentation of the uterus and menstrual pain[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(5): 1186-1192.
[2] Su-Xian Zhang, Lu Wu, You-Fang Hou, Bo Yan, Shao-Yan Yang, Li-Hua Yang, Qing-Hua Zhao. Hemoperitoneum caused by bleeding of adenomyosis: a case report[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(2): 444-447.
[3] Ja Young Kim, Yun Gyu Song, Chang-Woon Kim, Moon Ok Lee. Uterine artery embolization using gelatin sponge particles for symptomatic focal and diffuse adenomyosis[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(1): 59-65.
[4] Xiao-Cen Niu, Li-Hua Zhu, Zhi-Da Qian, Li-Li Huang. Disseminated intravascular coagulation developed after suction curettage in an adenomyosis patient: a case report and literature review[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(1): 189-193.
[5] Yan-Bing Xiao, Meng Mou, Heng-Fang Gu, Hui-Xing Li, Meng-Yuan You, Zhi-Gang Liang, Lei Han. The impact of major uterine wall resection and reconstruction of the uterus (MURU) on uterine hemodynamics and ovarian function in patients with adenomyosis: a clinical study[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(1): 132-137.
[6] S.Y. Song, G.W. Lee, J.B. Yang, D.E. Kim, D.B. Park, H.J. Yoo. Septic shock caused by abscess formation inside cystic adenomyosis after responsive treatment of pelvic inflammatory disease[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(6): 983-987.
[7] H. Takagi, S. Yamada, J. Sakamoto, S. Fujita, T. Sasagawa. Hemostatic effects of kyukikyogaito in dienogest treatment[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 560-564.
[8] H.S. Song, Y.A. Kim. Placenta percreta at 33 weeks of gestation after laparoscopic radiofrequency ablation for adenomyosis and Conservative Surgical Treatment: A case report and review of literature[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 600-603.
[9] A. Pontis, L. Nappi, F. Sorrentino, S. Angioni. Differential diagnosis of adenomyosis: the role of hysteroscopy and laparoscopy[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(4): 511-515.
[10] H. Kwon, J.E. Shin, H. Kim. A novel treatment of severe dysmenorrhea due to adenomyosis: a case series of 3 infertile patients treated with dopamine agonist and in vitro fertilization-embryo transfer resulting in successful pregnancy[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(4): 637-640.
[11] H. Takagi, J. Sakamoto, T. Sasagawa. Long-term treatment of endometriosis with dienogest for up to five years[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(3): 398-402.
[12] Jae-Seong Lee, Tae-Eung Kim, Jang Heub Kim, Byung Joon Park. Unintended pregnancies with term delivery following ultrasound-guided high-intensity focused ultrasound (USgHIFU) ablation of uterine fibroid and adenomyosis[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(6): 842-844.
[13] Sha A Dai Ti, Wu Fu Er, Zhao Lei, A Yi Nu Er, Mai Su Ti, Gu Li Na, A Ba Bai Ke Li. Clinical evaluation of three methods in the treatment of adenomyosis[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(4): 508-512.
[14] Ju-Qi Ma, Chun-Fen Guo, Ayshamgul Hasim. Clinical efficacy of levonorgestrel releasing intrauterine system for the treatment of adenomyosis in perimenopausal women[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(3): 387-390.
[15] H. Takagi, T. Sasagawa, Y. Osaka. Confirmation of menopause based on changes in follicle-stimulating hormone levels in patients who were administered dienogest[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(2): 312-315.
No Suggested Reading articles found!